Stay updated with breaking news from Gene Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode.
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy ultra-rare disease program - FDA... | January 31, 2023
20.01.2023 - PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted ...
Item 2.02 Results of Operations and Financial Condition. On January 9, 2023, Precision BioSciences, Inc. issued a press release announcing its preliminary unaudited cash balance as of December 31,... | January 9, 2023
Taysha Gene Therapies Announces Executive Leadership Changes - read this article along with other careers information, tips and advice on BioSpace